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A B S T R A C T   
Pathogenic bi-allelic variants in the SPG11 gene result in rare motor neuron disorders such as Hereditary Spastic Paraplegia type 11, Charcot-Marie Tooth, and 
Juvenile Amyotrophic Lateral Sclerosis-5. The main challenge in SPG11-linked disease research is the lack of antibodies against SPG11 encoded spatacsin. Here, we 
describe the CRISPR/Cas9 mediated generation and validation of an endogenously tagged SPG11- human iPSC line that contains an HA tag at the C-terminus of 
SPG11. The line exhibits multi-lineage differentiation potential and holds promise for studying the role of spatacsin and for the elucidation of SPG11-associated 
pathogenesis. 
Resource Table:   
1. Resource Table:  
Unique stem cell line identifier TMOi001-A-4 
https://hpscreg.eu/cell-line/TM 
Oi001-A-4 
Alternative name(s) of stem cell line SPG11-HA 
Institution Department of Stem Cell Biology 
Universitätsklinikum Erlangen 
Contact information of the reported 
cell line distributor 
Holger Wend 
Email: Holger.Wend@uk-erlangen.de 
Type of cell line iPSC 
Origin Human 
Additional origin info 
(applicable for human ESC or iPSC) 
Female 
Cell Source CD34 + cord blood 
Method of reprogramming episomally 
Clonality Clonal 
Evidence of the reprogramming 
transgene loss (including genomic 
copy if applicable) 
negative Southern blot originally reported 
for the parental line 
Cell culture system used N/A 
Type of Genetic Modification HA tag insertion 
Associated disease N/A 
(continued on next column)  
(continued ) 
Gene/locus SPG11 
Method of modification/site-specific 
nuclease used 
CRISPR/Cas9 
Site-specific nuclease (SSN) delivery 
method 
Plasmid transfection 
All genetic material introduced into 
the cells 
pCAG-SpCas9-GFP-U6-gRNA plasmid, 
single-stranded oligonucleotide donor 
DNA (ssODN) 
Analysis of the nuclease-targeted allele 
status 
N/A 
Method of the off-target nuclease 
activity surveillance 
Targeted PCR/sequencing 
Name of transgene N/A 




Inducible/constitutive system details N/A 
Date archived/stock date 12/08/2019 
Cell line repository/bank N/A 
Ethical/GMO work approvals The original iPSC line was obtained from 
Thermo Fisher scientific. 
Ethical approval information for the 
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(continued ) 
parental line is listed at hpscreg: https://h 
pscreg.eu/cell-line/TMOi001-A 
Addgene/public access repository 
recombinant DNA sources’ 
disclaimers (if applicable) 
Addgene plasmid # 79,144; http://n2t. 
net/addgene:79144; RRID: 
Addgene_79144  
Manuscript section expected contents clarification 
2. Resource utility 
The bi-allelically endogenously tagged SPG11-human iPSC line en-
ables precise detection of the SPG11-encoded spatacsin by employing 
antibodies against HA tag. Thus, it solves the previous problem of 
missing specific IP and ChiP grade antibodies against SPG11. The pre-
sented line can be further differentiated to study the role of spatacsin in 
different cell types and particularly during neural development. 
3. Resource details 
Bi-allelic pathogenic variants in SPG11, encoding spatacsin result in 
rare motor neuron disorders such as Hereditary Spastic Paraplegia type 
11 (SPG11-HSP), Charcot-Marie Tooth disease, and Juvenile Amyo-
trophic Lateral Sclerosis-5 (ALS5). SPG11-HSP is the most frequent 
complicated autosomal-recessive HSP. Besides spasticity and para-
paresis of the lower extremities, patients with SPG11-HSP present with 
additional symptoms such as cognitive decline, upper limb weakness, 
and peripheral neuropathy (Pozner et al., 2020). 
SPG11 encodes a ~280 kDa protein, termed spatacsin that is 
involved in the function of the autophagic lysosomal machinery and 
vesicular trafficking. However, due to a lack of specific antibodies, the 
exact function of spatacsin is yet unclear. To overcome this obstacle we 
generated an endogenously tagged SPG11 human-induced-pluripotent- 
stem-cell (hiPSC) line (SPG11-HA). The tagging was performed by 
employing CRISPR/Cas9 technology to insert an HA tag with homology- 
directed repair in a commercially available human episomal iPSC line 
(A18945; Thermo Fisher Scientific). 
The cells were nucleofected with a vector coding for SpCas9, GFP, 
and a single guide-RNA (gRNA; addgene) targeting the end of the last 
exon of SPG11 together with a single-stranded oligonucleotide (ssODN) 
donor DNA. The ssODN contained an HA coding region flanked by 
~66–67 nucleotide homology arms (Fig. 1A-B). Following a single-cell 
sorting procedure and clone expansion, the positive candidates were 
identified by PCR amplification and Sanger Sequencing (Fig. 1A). The 
genotype was confirmed by Sanger and Amplicon/NGS sequencing 
(Fig. 1A,C). No pathogenic variants were detected at the predicted off- 
target loci (Fig. S1A). Chromosomal microarray analysis did not reveal 
any de novo copy number variations (CNV) in the nucleofected reporter 
line in comparison to iPSC control cells (ctrl) that did not undergo the 
CRISPR process (Fig. 1D). However, a gain at 20q11.21 was found in 
both cell lines. This CNV is recurrently found in hiPSCs and cancers, 
suggesting that it confers a proliferative or survival advantage (Nguyen 
et al., 2014). Both ctrl and SPG11-HA iPSC exhibited typical pluripo-
tency cell-like morphology and were tested negative for mycoplasma 
(Fig. S1B-C). Both cell lines expressed pluripotency markers and 
differentiated in derivates of all three germ layers when tested with 
trilineage differentiation paradigm (Fig. 1E-F; Fig. S1D; Table 1). 
To validate the functionality of the reporter line, expression of tag-
ged spatacsin was investigated by Western blot. As expected, HA-tagged 
spatacsin was detectable at a size of 280 kDa (Fig. 1G). Due to the range 
of neurological symptoms exhibited upon loss of function of spatacsin, 
the neural differentiation capacity was assessed. Nearly 90% of differ-
entiated control and SPG11-HA neural progenitor cells (NPCs) expressed 
both NPC markers SOX2 and Nestin (Fig. 1SE), rendering it a valid 
resource for studying neuronal phenotypes. Furthermore, HA-tagged 
spatacsin expression was also observed in SPG11-HA NPCs (Fig. S1F). 
4. Materials and methods 
4.1. Cell culture 
Human Episomal iPSCs A18945 (Thermo Fisher Scientific) were 
cultured in mTeSR (STEMCELL Technologies) with 1% Penicillin/ 
Streptomycin (Life Technologies) at 37 ◦C with 5% CO2 on Geltrex™ 
(500 µg for 57 cm2, Thermo Fisher Scientific) coated plates. Cells were 
passages as clumps at a ratio of 1:3–1:10 every 3–5 days using Gentle 
Cell Dissociation Reagent (STEMCELL Technologies) without any sur-
vival promoter. Cells were received at passage 40 (P) and all experi-
ments were conducted using passages numbers of P + 5 - P + 10 after 
genome editing. Mycoplasma testing was performed using MycoAlertTM 
Mycoplasma Detection Kit (Lonza). 
4.2. Genome editing 
For the generation of an SPG11-reporter line, an adapted version of a 
previously described protocol (Turan et al., 2019) was used. Briefly, the 
single gRNA spacers were selected using the CRISPOR tool 
(http://www.crispor.tefor.net) and cloned into pCAG-SpCas9-GFP-U6- 
gRNA plasmid (Addgene plasmid #79144). iPSCs were nucleofected 
with 5 µg pCAG-SpCas9-GFP-U6-gRNA plasmid and 0.2 nM Donor DNA 
Oligonucleotide (IDT) using the nucleofector 2B (program B-16) and the 
human stem cell nucleofector kit 2 (Lonza; Cat.# VPH-5022). To in-
crease the homologous recombination efficiency, the cells were treated 
with a 20 µmol HDR enhancer (IDT; Cat.#1081072) for 24 h. After an 
additional 24 h, single GFP + iPSCs were sorted into a Geltrex (Thermo 
Fisher Scientific) coated 96-well plate containing CloneR (10% in 
mTeSR, STEMCELL Technologies). 7–10 days later, clones were 
mirrored into two 48-well plates. One plate was cryopreserved using 
Bambanker (Nippon) and the remaining plate was used for genomic 
DNA (gDNA) extraction using QIAamp DNA Blood Mini Kit (Qiagen). To 
validate the tag integration, exon 40 of SPG11 was amplified using 
Q5®High-Fidelity DNA Polymerase (New England Biolabs). Since the 
reverse primer was complementary to the HA tag intersection, only exon 
40 including HA was amplified (for primer sequence see Table 2). 
Flanking PCR to sequence the complete region of interest served as 
additional confirmation (Table 2). For NGS-based genotyping of the 
SPG11-reporter line, the Amplicon-EZ (GENEWIZ) was used (for primers 
see Table 2). 
4.3. Off-target analysis 
The four highest-scoring predicted exonic off-target regions identi-
fied by CRISPOR (http://www.crispor.tefor.net) were examined ac-
cording to a previous description (Pozner et al., 2018). 
Flow cytometry, immunocytochemistry and western blot 
Flow cytometry and immunohistochemistry analysis were performed 
as previously described (Boerstler et al., 2020) (for antibodies see 
Table 2). Western blot was performed similarly to described conditions 
(Pérez-Brangulí et al., 2019). 
4.4. Chromosomal microarray analysis 
Extracted gDNA from ctrl and SPG11-HA iPSCs was analyzed with 
Affymetrix CytoScan HD (Affymetrix Inc., Santa Clara, CA, USA) and the 
data set of samples were evaluated with Affymetrix Chromosome 
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Analysis Suite (ChAS v3.1.0.15) as previously described (Asadollahi 
et al. 2014). We assessed mosaic and non-mosaic copy number variants 
(CNVs) sizing > 20 kb for their overlap with annotated exons and their 
presence in control databases. Rare CNVs > 20 kb affecting exonic re-
gions were considered for their pathogenicity. The two samples were 
compared for newly occurring CNVs after the CRISPR process. 
4.5. Trilineage differentiation 
Human germ layer differentiation was performed using the STEM-
diff™ Trilineage Differentiation Kit (STEMCELL Technologies) accord-
ing to manufacturer’s guidelines. Immunohistochemistry staining of the 
specific germ layer markers was performed using Human Three Germ 
Layer 3-Color Immunohistochemistry Kit (R&D Systems). 
4.6. Differentiation into neural progenitor cells 
Neural differentiation was performed using a modified version of a 
previously described protocol (Turan et al., 2019). NPCs were split once 
per week using Accutase (Thermo Fisher Scientific). 
Declaration of Competing Interest 
The authors declare that they have no known competing financial 
interests or personal relationships that could have appeared to influence 
the work reported in this paper. 
Fig. 1. . A. Paradigm depicting the genome editing strategy. The iPSCs are nucleofected with a plasmid expressing gRNA and SpCas9-GFP. After 48 h in 12-well plate, 
the GFP positive cells are single-cell sorted into 96-well plate for 7–10 days expansion. Afterwards, the cells are mirrored into 48-well plates for further genotyping 
and cryopreservation. Following the genotyping of the clones by performing PCR and sequencing, candidate clones are thawed and validated. OT = off-target; CNV 
= copy number variation. B. Schematic representation of the CRISPR/Cas9 mediated targeting of the last exon of the SPG11 gene. C. Results of the Amplicon-EZ NGS- 
based sequencing depicting the incorporated sequence of HA tag into the C-terminal domain of SPG11 (top), and demonstration that 74,894 reads out of 80,000 reads 
contained the tag (bottom). D. Chromosomal microarray analysis of the analysed lines presenting the detected CNVs. E. Pluripotency analysis by using Tra 1–60 flow 
cytometry analysis. F. Immunofluorescence images of the gene-edited clone (SPG11-HA) and control cells (ctrl) demonstrating comparably high expression of 
pluripotency markers NANOG, OCT3/4 and SOX2 (scale bar = 50 µm). G. Immunoblot using an antibody against HA, reveals a precise and specific detection 
corresponding to the size of spatacsin and HA tag (~280 kDa). 
Table 1 
Characterization and validation.  
Classification 
(optional italicized) 
Test Result Data 
Morphology Photography Visual record of line: normal Fig. S1C 
Pluripotency status evidence for the 
described cell line 
Qualitative analysis (i.e. Immunocytochemistry, 
western blotting) 
Staining of pluripotency markers: Oct 3/4, Nanog, Sox2 Fig. 1F 
Quantitative analysis (i.e. Flow cytometry, RT- 
qPCR) 
Flow cytometry analysis of cell surface marker Tra 1-60 Fig. 1E 
Karyotype Karyotype (G-banding) and higher-resolution, 
array-based assays (KaryoStat, SNP, etc.) 
Normal karyotype according to G-banding was reported for the 
parental cell line. SPG_HA line was evaluated with higher 
resolution analysis: Affymetrix CytoScan HD 
Resolution > 20 kb 
Fig. 1D 
Genotyping for the desired genomic 
alteration/allelic status of the gene 
of interest 
PCR across the edited site or targeted allele- 
specific PCR 
Bi-allelic HA tag insertion Fig. 1C 
Transgene-specific PCR N/A N/A 
Verification of the absence of random 
plasmid integration events 
PCR/Southern Negative Southern Reported for the 
parental line 
Negative PCR submitted in 
archive with 
journal 
Parental and modified cell line genetic 
identity evidence 
STR analysis, microsatellite PCR (mPCR) or 
specific (mutant) allele seq 




journal    
Mutagenesis / genetic modification 
outcome analysis 
Sequencing (genomic DNA PCR or RT-PCR 
product) 
Amplicon-EZ NGS-based sequencing Fig. 1C 
PCR-based analyses   
Southern Blot or WGS; western blotting (for 
knock-outs, KOs)   
Off-target nuclease analysis- PCR across top 5/10 predicted top likely off- 
target sites, whole genome/exome sequencing 
Top predicted likely-off target sites Fig. S1A 
Specific pathogen-free status Mycoplasma Mycoplasma testing by luminescence: all negative Fig. S1C 
Multilineage differentiation potential e.g. Embryoid body formation OR Teratoma 
formation OR Scorecard OR Directed 
differentiation 
Directed differentiation Fig. S1D 
Donor screening (OPTIONAL) HIV 1 + 2 Hepatitis B, Hepatitis C N/A N/A 
Genotype - additional histocompatibility 
info (OPTIONAL) 
Blood group genotyping N/A N/A 
HLA tissue typing N/A N/A  
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Table 2 
Reagents details.  
Antibodies and stains used for immunocytochemistry/flow-cytometry  
Antibody Dilution Company Cat # and RRID 
Primary antibody Rabbit Anti-HA tag 1:500 Abcam Cat# ab9110; RRID: 
AB_307019_307019 
Primary antibody Mouse Anti-Adaptin γ 1:1000 BD Bioscience Cat# 610385, RRID: 
AB_397768 
Primary antibody Mouse Anti-beta-Actin 1:5000 Sigma-Aldrich Cat# A1978, RRID: 
AB_476692 
Pluripotency marker Rabbit Anti-Sox2 1:500 Cell Signalling Cat# 3579, RRID: 
AB_2195767 
Pluripotency marker Goat Anti-Nanog 1.500 R&D Systems Cat# AF1997, RRID: 
AB_355097 
Pluripotency marker Mouse Anti-Oct-3/4 (C-10) 1:500 Santa Cruz Cat# sc-5279, RRID: 
AB_628051 
Pluripotency marker Mouse Anti-Tra 1-60-R Alexa 488 1:20 Biolegend Cat# 330614, RRID: 
AB_2119064 
Differentiation marker Mouse Anti Nestin-PerCP-Cy 1:50 BD Bioscience Cat#561231, RRID: 
AB_10562199 
Differentiation marker Mouse Anti-Sox2-PE 1:50 BD Bioscience Cat#561610, RRID: 
AB_10712763 
Secondary antibody Alexa Fluor™anti-mouse 488 1:500 Thermo Scientific Cat#A32766, RRID: 
AB_2762823 
Secondary antibody Alexa Fluor™anti-goat 546 1:500 Thermo Scientific Cat#A11056, RRID: 
AB_2534103 
Secondary antibody Alexa Fluor™anti-rabbit 647 1:500 Thermo Scientific Cat#A32794, RRID: 
AB_2762835 
Secondary antibody Anti-mouse HRP 1:10000 Thermo Scientific Cat# A16017, RRID: 
AB_2534691 
Secondary antibody Anti-rabbit HRP 1:5000 Thermo Scientific Cat#A16035, RRID: 
AB_2534709  
Site-specific nuclease 
Nuclease information SpCas9  
Delivery method Nucleofection  
Selection/enrichment strategy Single-cell sorting   
Primers and Oligonucleotides used in this study  
Target Forward/Reverse primer (5′-3′) 
e.g. Episomal Plasmids (qPCR or RT-PCR) e.g. OCT4 Plasmid N/A 
e.g. Pluripotency Markers (qPCR) e.g. NANOG, etc. N/A 
e.g. House-Keeping Genes (qPCR) e.g. HSP90AB1, etc. N/A 
e.g. Genotyping (desired allele/transgene presence detection) PCR specific for the targeted allele N/A 
Targeted mutation analysis/sequencing Flanking PCR primer 
Junction PCR primer 









gRNA oligonucleotide/crRNA sequence gRNA oligonucleotide sequence caccgAGCAGGTTAGATGATTTCAT/ 
aaacATGAAATCATCTAACCTGCTc 
Genomic target sequence(s) Including PAM and other sequences likely to 
affect UCN activity 
APE file submitted in archive with journal 
Top off-target mutagenesis predicted site sequencing (for CRISPR/ 






TGGCAGTGACTGGAAG (379 bp) 
TTCTGTCCTGCTGCACATTC/ 
TTTGCTTTGTCCTGCAGATG (444 bp) 
GGCTGCTTTTCAACCAAGAG/ 
CCGTGGACCTTGACTGATTT (309 bp) 
TTTCTGCCACATCTGAGTCG/ 
TGTCGAGGAAGCTTTCAGGT (391 bp) 






cccacgttctgcttcactct/tcacgcagccacagaaaaga (448 bp) 
CCACGACGGAGACTACAAGG/ 
CCGCTCGTGCTTCTTATCCT (448 bp) 
CAGAGCTTCATCGAGCGGAT/ 
CGAACAGGTGGGCATAGGTT (466 bp) 
GAACCAGACCACCCAGAAGG/ 
CTCGGCCTTGGTCAGATTGT (415 bp) 
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